Stock CHRS COHERUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:12:35 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.955 USD -3.22% Intraday chart for Coherus BioSciences, Inc. -2.00% -41.14%
Apr. 24 Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting CI
Mar. 20 HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating MT

Business Summary

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Number of employees: 306

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Pharmaceutical Products
100.0 %
211 100.0 % 257 100.0 % +21.89%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
211 100.0 % 257 100.0 % +21.89%

Managers

Managers TitleAgeSince
Denny Lanfear CEO
 Chief Executive Officer 68 10-08-31
Bryan Mcmichael DFI
 Director of Finance/CFO 46 21-02-28
Richard L. Hameister CTO
 Chief Tech/Sci/R&D Officer - 21-11-30
Rosh Dias CTO
 Chief Tech/Sci/R&D Officer - 22-03-14
Karen Kotz SAM
 Sales & Marketing - 22-07-31
Paul Reider PRN
 Corporate Officer/Principal 55 20-12-31
Michael A. Fleming PRN
 Corporate Officer/Principal - 14-04-27
Theresa M. LaVallee PRN
 Corporate Officer/Principal 57 21-12-16
Rebecca Sunshine HRO
 Human Resources Officer 61 13-12-31

Members of the board

Members of the board TitleAgeSince
Mark Stolper BRD
 Director/Board Member 52 21-01-04
Mats Wahlström BRD
 Director/Board Member 70 11-12-31
Ali Satvat BRD
 Director/Board Member 46 14-04-30
Lee Newcomer BRD
 Director/Board Member 71 22-02-01
Denny Lanfear CEO
 Chief Executive Officer 68 10-08-31
Georgia Erbez BRD
 Director/Board Member 57 Feb. 19
Jill O'Donnell-Tormey BRD
 Director/Board Member 68 22-05-17
Michael Ryan BRD
 Director/Board Member - 23-07-17
Kimberly Commins-Tzoumakas BRD
 Director/Board Member 56 20-07-29
Charles Newton BRD
 Director/Board Member 53 22-05-04

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 113,498,415 108,865,391 ( 95.92 %) 0 95.92 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
10.19 %
11,346,759 10.19 % 27 M $
Vanguard Fiduciary Trust Co.
9.300 %
10,357,412 9.300 % 25 M $
Temasek Holdings Pte Ltd.
6.628 %
7,381,116 6.628 % 18 M $
Barclays Bank Plc
3.129 %
3,484,395 3.129 % 8 M $
Kohlberg Kravis Roberts & Co. LP
2.726 %
3,036,076 2.726 % 7 M $
Millennium Management LLC
2.552 %
2,842,319 2.552 % 7 M $
Pictet Asset Management Holding SA
2.229 %
2,481,848 2.229 % 6 M $
C Worldwide Asset Management Fondsmæglerselskab A/S (Sweden)
1.936 %
2,156,117 1.936 % 5 M $
Bank of America, NA (Charlotte, North Carolina)
1.903 %
2,118,804 1.903 % 5 M $
Geode Capital Management LLC
1.869 %
2,081,601 1.869 % 5 M $

Company contact information

Coherus BioSciences, Inc.

333 Twin Dolphin Drive Suite 600

94065, Redwood City

+650 649 3530

http://www.coherus.com
address Coherus BioSciences, Inc.(CHRS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Coherus BioSciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.02 USD
Average target price
7.8 USD
Spread / Average Target
+286.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
COHERUS BIOSCIENCES, INC. Stock Coherus BioSciences, Inc.
-42.19% 229M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.28% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-0.06% 97.42B
ARGENX SE Stock argenx SE
+1.31% 22.2B
BIONTECH SE Stock BioNTech SE
-18.25% 21.23B
GENMAB A/S Stock Genmab A/S
-10.74% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.17% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.60% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.51% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CHRS Stock
  4. Company Coherus BioSciences, Inc.